Loading...
Market
Neumora's next major strategic move by end of 2025
2
Resolution / Starting Odds
Partnership with another pharmaceutical company • 25%
Acquisition by another company • 25%
Launch of a new drug development program • 25%
No major strategic move • 25%
Official announcements from Neumora Therapeutics or major news outlets
Story
Neumora's Navacaprant Fails in KOASTAL-1 Phase 3 Trial; Shares Plunge 83%
Jan 2, 2025, 01:40 PM
Neumora Therapeutics (NMRA) shares plummeted by up to 83% after the company announced that its experimental drug navacaprant failed to meet the primary and key secondary endpoints in the Phase 3 KOASTAL-1 study for the treatment of major depressive disorder (MDD). This marks the company's first late-stage readout. The study did not demonstrate a statistically significant improvement in the primary endpoint of change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6, nor in the key secondary endpoint of the Snaith-Hamilton Pleasure Scale (SHAPS) score. Despite the setback, Neumora is continuing with two other identical Phase 3 trials, KOASTAL-2 and KOASTAL-3. Some analysts expressed skepticism over the company's interpretation of subgroup analyses suggesting efficacy in women but not in men. The failure of navacaprant, which targets the kappa opioid receptor (KOR) antagonist pathway, underscores the challenges in developing new treatments for depression and comes amid tough competition in the KOR antagonist space.
View original story
Similar markets
Remains until mid-2026 • 25%
Extended beyond mid-2026 • 25%
Reduced to before mid-2026 • 25%
Not disclosed • 25%
Virtual reality and wearables • 25%
Other • 25%
AI and machine learning • 25%
Social media enhancements • 25%
Partnership or joint venture • 25%
Acquisition of another company • 25%
Merger with another company • 25%
No significant strategic move • 25%
Partnership within Japan • 25%
Partnership in Asia-Pacific • 25%
Partnership outside Asia-Pacific • 25%
No new partnership • 25%
Shares increase by up to 50% • 25%
Shares increase by over 50% • 25%
Shares decrease • 25%
Shares remain stable • 25%
Digital transformation • 25%
No significant change • 25%
Focus on sustainability • 25%
Expansion into new markets • 25%
Partnerships with Other Insurers • 25%
Expansion of Existing Operations • 25%
Focus on Domestic Market • 25%
Further Acquisitions • 25%
No new partnerships or acquisitions • 25%
Partnership with cloud services company • 25%
Partnership with AI company • 25%
Acquisition of a tech startup • 25%
Deir ez-Zor • 25%
Raqqa City • 25%
Tabqa Dam • 25%
Other • 25%
Major restructuring • 25%
Other • 25%
New game franchise • 25%
Acquisition of another company • 25%